GATA2 and acute myeloid leukemia: IKZF1-mutated AML patients showed significantly increased rates of alterations in RUNX1 (26.6% vs. 8.7%, p < 0.001), GATA2 (15.6% vs. 5.8%, p = 0.016), KRAS (15.6% vs. 5.0%, p = 0.008), KIT (15.6% vs. 4.6%, p = 0.005), SF3B1 (15.6% vs. 2.5%, p < 0.001), and ETV6 (8.9% vs. 0.7%, p = 0.001).